登录
×
用户名/邮箱
密码
验证码:
换一张
Stay signed in
Forgotten Password?
Log In
×
Log In By KMS
Chinese
|
English
Subscribe to the Website's RSS
Subscribe to the Website's Atom Feeds
Log In By IDS
|
Log In By KMS
|
Register
ALL
ORCID
Title
Creator
Subject Area
Keyword
Funding Project
Document Type
Source Publication
Indexed By
Date Issued
Date Accessioned
Publisher
MOST Discipline Catalogue
Original Document Type
Creator
Study Hall
Image search
Paste the image URL
Home
(current)
Collections
Authors
DocType
Subjects
K-Map
News
Search in the results
搜索
Collection
Second Clinica... [4]
Fulltext
No [4]
Document Type
Journal articl... [3]
Thesis [1]
Date Issued
2019 [1]
2018 [3]
Language
中文 [4]
Source Publication
中国肿瘤临床 [1]
兰州大学学报(医学版) [1]
西北国防医学杂志 [1]
Indexed By
CSCD [1]
北大核心 [1]
First Author Affilication
兰州大学 [3]
第二临床医学院 [3]
Corresponding Author Affilication
兰州大学 [1]
第二临床医学院 [1]
Knowledge Map
×
兰州大学机构库
Start a Submission
Submissions
Unclaimed
Claimed
Attach Fulltext
Bookmarks
QQ
Weibo
Feedback
Browse/Search Results:
1-4 of 4
Help
Selected(
0
)
Clear
Items/Page:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
Sort:
Select
Author Ascending
Author Descending
Submit date Ascending
Submit date Descending
Issue Date Ascending
Issue Date Descending
Journal Impact Factor Ascending
Journal Impact Factor Descending
WOS Cited Times Ascending
WOS Cited Times Descending
Title Ascending
Title Descending
碳酸酐酶Ⅸ、DLL4的表达与胃腺癌术后复发的相关性研究
期刊论文
兰州大学学报(医学版), 2019, 卷号: 45, 期号: 05, 页码: 66-72
Authors:
王拓
;
魏友芬
;
赵金匣
;
张德奎
;
李桂香
Favorite
  |  
  
Submit date:2023/11/22
胃腺癌
碳酸酐酶Ⅸ
DLL4
免疫组化
复发
脾多肽注射液治疗恶性肿瘤的研究进展
期刊论文
西北国防医学杂志, 2018, 卷号: 39, 期号: 03, 页码: 208-210
Authors:
魏友芬
;
李桂香
Favorite
  |  
  
Submit date:2023/11/21
恶性肿瘤
脾多肽注射液
免疫功能
ELTD1、VEGF、DLL4在胃腺癌中的表达及 临床意义
学位论文
硕士, 兰州: 兰州大学, 2018
Authors:
魏友芬
Favorite
  |  
  
Submit date:2019/01/17
胃癌
ELTD1
DLL4
VEGF
免疫组化
PD-1/PD-L1抑制剂在结直肠癌中的研究进展
期刊论文
中国肿瘤临床, 2018, 卷号: 45, 期号: 3, 页码: 157-160
Authors:
魏友芬(综述)
;
李桂香(审校)
Favorite
  |  
  
Submit date:2019/10/16
结肠肿瘤
免疫治疗
PD-1/PD-L1抑制剂
colonic neoplasms
Immunotherapy
PD-1/PD-L1 inhibitors